IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years
- None.
- None.
Insights
The announcement by IDEXX Laboratories to include Cystoisospora in its Fecal Dx antigen testing platform represents a significant advancement in veterinary diagnostics. The ability to detect this parasite earlier and more accurately can lead to improved health outcomes for young dogs and cats, who are primarily affected by this parasite. Early detection is crucial as it allows for timely intervention, which can prevent the severe symptoms associated with Cystoisospora, such as diarrhea, weight loss and dehydration. The veterinary community has long relied on fecal flotation tests, which are less sensitive than antigen testing. The new antigen tests can detect up to five times more infections, which can substantially reduce the risk of undiagnosed infections leading to more severe health complications.
Fecal Dx antigen testing's expansion could potentially lead to an increase in IDEXX's market share within the veterinary diagnostics sector. Given that the Companion Animal Parasite Council recommends frequent fecal testing, there is a clear ongoing demand for reliable and efficient diagnostic tools. The introduction of this enhanced testing platform may encourage veterinary practices to adopt IDEXX's services over competitors, especially considering the efficiency gains in terms of staff time. The veterinary diagnostics market is growing and innovations that offer both accuracy and efficiency are likely to be well-received by practices looking to improve operational efficiency, which currently stands at a significant 87% of practices seeking improvements. This move by IDEXX is likely to be seen positively by investors as it demonstrates the company's commitment to innovation and could lead to increased revenue from diagnostic services.
IDEXX Laboratories' expansion of its Fecal Dx antigen testing platform could have a positive financial impact on the company. By broadening the scope of detectable parasites, IDEXX not only enhances its product offering but also potentially increases its customer base among veterinary practices. The fact that Cystoisospora will be included at no additional charge could incentivize existing customers to continue using IDEXX's services and attract new customers who are looking for a more comprehensive testing solution. As a tool for preventive care, Fecal Dx antigen testing aligns with the trend towards more proactive and preventative veterinary services, which could lead to a steady stream of recurring revenue for IDEXX. The company's strategy of supplementing its testing services with convenient solutions like the IDEXX FecalChek® Home Collection Kit further positions it to capitalize on the growing pet healthcare market.
Fecal Dx antigen testing will soon detect the most common intestinal parasites earlier, uncovering more infections
The Companion Animal Parasite Council (CAPC) recommends fecal testing for puppies and kittens four times in their first year and twice-annual testing for adult pets, which underscores the importance of reliable testing for intestinal parasites during preventive care visits.1 The addition of Fecal Dx antigen testing detects up to five times more infections than flotation tests alone by identifying parasite-specific antigens rather than relying on the presence of eggs.2–4 With its industry-leading antigen detection capabilities, Fecal Dx antigen testing identifies infections earlier than other testing modalities, 2–4 enabling veterinarians to develop targeted treatment and prevention plans with confidence.
"We are thrilled to announce the second expansion of the Fecal Dx antigen testing platform in less than two years, reinforcing our commitment to continuous innovation," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "Early detection is key for intestinal parasites, which affect one in five dogs,5 and our highly differentiated antigen testing platform, soon with Cystoisospora, offers a comprehensive solution that accurately detects the most clinically relevant infections."
Fecal Dx antigen testing continues to serve as a foundational tool for veterinary practices, eliminating the need for time-consuming fecal flotation testing and ultimately redeploying staff time back to patient and client care. Freeing up staff time is especially important when
"Antigen testing has emerged as a more reliable diagnostic test that provides earlier insights, and with the addition of Cystoisospora, Fecal Dx antigen testing detects all the intestinal parasites I commonly see in my patients," said Dr. Michael Rose, Monticello Animal Hospital.* "By sending specimens to IDEXX Reference Laboratories, our practice benefits from not having to do manual testing, which saves time and improves our workflow."
Cystoisospora will automatically be included in Fecal Dx antigen testing panels and profiles at the time of launch with no additional charge to customers. For more information, please visit the Fecal Dx antigen testing page.
About IDEXX
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to
Contact
Media Relations
media@idexx.com
Investor Relations
investorrelations@idexx.com
1. | CAPC guidelines: controlling internal and external parasites in | |||||||||
2. | Elsemore D, Bezold T, Geng J, Hanna R, Tyrrell P, Beall M. Immunoassay for detection of Dipylidium caninum coproantigen in dogs and cats. J Vet Diagn Invest. 2023;35(6):671–678. doi:10.1177/10406387231189193 | |||||||||
3. | Elsemore DA, Geng J, Flynn L, Cruthers L, Lucio-Forster A, Bowman DD. Enzyme-linked immunosorbent assay for coproantigen detection of Trichuris vulpis in dogs. J Vet Diagn Invest. 2014;26(3):404–411. | |||||||||
4. | Elsemore DA, Geng J, Cote J, Hanna R, Lucio-Forster A, Bowman DD. Enzyme-linked immunosorbent assays for coproantigen detection of Ancylostoma caninum and Toxocara canis in dogs and Toxocara cati in cats. J Vet Diagn Invest. 2017;29(5):645–653. doi:10.1177/1040638717706098 | |||||||||
5. | Stafford K, Kollasch TM, Duncan KT, et al. Detection of gastrointestinal parasitism at recreational canine sites in the | |||||||||
6. | Finding the Time: Empowering Veterinary Teams to Get the Most Out of Every Day. IDEXX; 2023. | |||||||||
*Dr. Rose has received compensation for consulting services he has provided to IDEXX from time to time. | ||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/idexx-expands-fecal-dx-antigen-testing-platform-with-cystoisospora-detection-marking-the-second-platform-expansion-in-less-than-two-years-302033184.html
SOURCE Idexx Laboratories, Inc.
FAQ
What did IDEXX Laboratories announce regarding its Fecal Dx antigen testing platform?
When is the launch of Fecal Dx antigen testing with Cystoisospora planned?
What does the Companion Animal Parasite Council recommend regarding fecal testing for pets?
What is the significance of the addition of Fecal Dx antigen testing with Cystoisospora?
How does IDEXX's FecalChek Home Collection Kit benefit veterinarians and pet owners?
